John Farley

John Farley

Auto-generated profile, based on publicly available information

John Farley

Common Spirit

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
WBWilliam E. Brady
William E. Brady
JFJohn Farley
John Farley
AAAmy Armstrong
Amy Armstrong
DUDenise S. Uyar
Denise S. Uyar
DGDavid M. Gershenson
David M. Gershenson

10 November 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CCChristine D. Craig
Christine D. Craig
BMBradley J. Monk
Bradley J. Monk
JFJohn H. Farley
John H. Farley
DCDana M. Chase
Dana M. Chase

15 August 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RGRachel Grisham
Rachel Grisham
IVIgnace Vergote
Ignace Vergote
SBSusana Banerjee
Susana Banerjee
EDEsther Drill
Esther Drill
EKElsa Kalbacher
Elsa Kalbacher
BMBradley J. Monk
Bradley J. Monk
Purpose: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). Patients and Methods: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan–Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations between mutation status and outcomes, including PFS and binary response by local RECIST 1.1. Results: MILO/ENGOT-ov11 enrolled 341 patients, ranging in age from 22 to 79, from June, 2013 to April, 2016. Patients were randomized 2:1 to binimetinib or physician's choice of chemotherapy (PCC). The most commonly altered gene was KRAS (33%). In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n = 11, 8.1%), BRAF V600E (n = 8, 5.9%), RAF1 (n = 2, 1.5%), and NF1 (n = 7, 5.2%). In those with and without MAPK pathway alterations, the RRs with binimetinib were 41% and 13%, respectively. PFS was significantly longer in patients with, compared with those without, MAPK pathway alterations treated with binimetinib [HR, 0.5; 95% confidence interval (CI) 0.31–0.79]. There was a nonsignificant trend toward PFS improvement in PCC-treated patients with MAPK pathway alterations compared with those without (HR, 0.82; 95% CI, 0.43–1.59). Conclusions: Although this hypothesis-generating analysis is limited by multiple testing, higher RRs and longer PFS were seen in patients with low-grade serous ovarian cancer (LGSOC) treated with binimetinib, and to a lesser extent in those treated with PCC, who harbored MAPK pathway alterations. Somatic tumor testing should be routinely considered in patients with LGSOC and used as a future stratification factor.

1 October 2008 in Military Medicine
Verified
Journal Article
Open access
PDF file
CGCarolyn C. Gotay
Carolyn C. Gotay
JFJohn H. Farley
John H. Farley
CKCrissy T Kawamoto
Crissy T Kawamoto
AMAdela Mearig
Adela Mearig
Objective: This study assessed quality of life in long-term cervical cancer survivors eligible for health care in the military health system. Methods

14 April 2016 in Gynecologic Oncology Research and Practice
Verified
Journal Article
Open access
PDF file
LMLindsey E. Minion
Lindsey E. Minion
DCDana M. Chase
Dana M. Chase
JFJohn H. Farley
John H. Farley
LWLyndsay J. Willmott
Lyndsay J. Willmott
BMBradley J. Monk
Bradley J. Monk
After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treating recurrent, refractory cervical cancer with nano-particle albumin bound (NAB) paclitaxel with or without bevacizumab. This retrospective case series was conducted in accordance with the regulations set forth by the Institutional Review Board at St. Joseph’s Hospital and Medical center. The chemotherapy log at the outpatient infusion center at the University of Arizona Cancer Center was reviewed to identify all advanced cervical cancer patients treated with NAB-paclitaxel from November 2011 until February 2015. The following data points were extracted from patient charts: demographic information, number of cycles, progression free survival (PFS), overall survival (OS), dose reductions and dose-limiting toxicities. In addition the average number of treatment cycles and age at recurrence were calculated. A total of 12 subjects were identified as receiving treatment with NAB-paclitaxel. Mean age at time of recurrence was 47.2 years (36–55). Nine subjects had squamous cell histology and three subjects had adenocarcinoma histology. All subjects had failed treatment with platinum and taxane, or platinum and topotecan chemotherapy. Two subjects were lost to follow up. The Median number of cycles of NAB-paclitaxel was 6.5 (2–19). The total number of cycles of NAB-paclitaxel in the study population was 65. Seven subjects were treated in combination with bevacizumab. Of these, three subjects are still alive and one subject is currently receiving active treatment with NAB-paclitaxel. The median PFS and OS for all subjects that met mortality endpoint was 4.8 months and 8.9 months (n = 7), respectively. One subject discontinued NAB-paclitaxel secondary to peripheral neuropathy, and one subject developed a vesicovaginal fistula while obtaining combination NAB-paclitaxel and bevacizumab therapy. NAB-paclitaxel with or without bevacizumab is tolerable and potentially active in treating recurrent cervical cancer after failing platinum-taxane or topotecan chemotherapy. This small case series deserves confirmation through prospective clinical trials.

1 October 2021 in Cancer Epidemiology
Verified
Journal Article
Open access
DRDorothy Rhoades
Dorothy Rhoades
JFJohn Farley
John Farley
SSStephen M. Schwartz
Stephen M. Schwartz
KMKimberly M. Malloy
Kimberly M. Malloy
WWWenyu Wang
Wenyu Wang
BHBarbara V. Howard
Barbara V. Howard
Cancer mortality among American Indian (AI) people varies widely, but factors associated with cancer mortality are infrequently assessed. Cancer deaths were identified from death certificate data for 3516 participants of the Strong Heart Study, a population-based cohort study of AI adults ages 45-74 years in Arizona, Oklahoma, and North and South Dakota. Cancer mortality was calculated by age, sex and region. Cox proportional hazards model was used to assess independent associations between baseline factors in 1989 and cancer death by 2010. After a median follow-up of 15.3 years, the cancer death rate per 1000 person-years was 6.33 (95 % CI 5.67-7.04). Cancer mortality was highest among men in North/South Dakota (8.18; 95 % CI 6.46-10.23) and lowest among women in Arizona (4.57; 95 % CI 2.87-6.92). Factors independently associated with increased cancer mortality included age, current or former smoking, waist circumference, albuminuria, urinary cadmium, and prior cancer history. Factors associated with decreased cancer mortality included Oklahoma compared to Dakota residence, higher body mass index and total cholesterol. Sex was not associated with cancer mortality. Lung cancer was the leading cause of cancer mortality overall (1.56/1000 person-years), but no lung cancer deaths occurred among Arizona participants. Mortality from unspecified cancer was relatively high (0.48/100 person-years; 95 % CI 0.32-0.71). Regional variation in AI cancer mortality persisted despite adjustment for individual risk factors. Mortality from unspecified cancer was high. Better understanding of regional differences in cancer mortality, and better classification of cancer deaths, will help healthcare programs address cancer in AI communities.